Stanford researchers have developed an LVCTM3 system for producing lentiviral vectors and other viral particles, offering a cost-effective, simplified and scalable solution for various applications from gene therapy to vaccine development.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.